CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD) will be presented at the 22^nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held April 29-May 2, 2019 in Washington, D.C.

Oral Presentations:

• SGT-001 Cardiac and Skeletal Muscle Microdystrophin Expression and Functional Efficacy in Preclinical Models of DMD
  Abstract Number: 39
  Date/Time: Monday, April 29^th at 11:00 a.m. ET
  
  
• Multiparameter In Vivo Screen of AncAAV Libraries in Muscle for Potency, Specificity and Impact of Disease State
  Abstract Number: 376
  Date/Time: Tuesday, April 30^th at 4:00 p.m. ET

Poster Presentation:

• Identification of Novel Muscle Specific Promoters and AAV Gene Expression in Skeletal and Cardiac Muscles
  Abstract Number: 822
  Date/Time: Wednesday, May 1^st at 5:00-6:00 p.m. ET

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.

Media Contact:
Kate Niazi-Sai
+1 617-337-4680
media@solidbio.com

Investor Contact:
Geoffrey M. Grande, CFA
+1 617-766-3398
investors@solidbio.com